Aug 08 2025 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 8 August 2025
⏱️ 32 minutes
🧾️ Download transcript
Summary
Listener feedback on SURPASS CVOT, AF ablation and the limits of meta-analyses, a Watchman alert from FDA, and oral anticoagulation choices in elderly patients are discussed by John Mandola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I SURPASS CVOT
- This Week in Cardiology Podcast, August 1 https://www.medscape.com/viewarticle/1002781
- Mounjaro Appears More Heart Protective Than Trulicity in Trial Of Eli Lilly Diabetes Drugs
https://www.medscape.com/s/viewarticle/mounjaro-proves-more-heart-protective-than-trulicity-trial-2025a1000kct
II Catheter and Surgical AF ablation
- Catheter and Surgical Ablation for AF: Meta-Analysis https://www.acpjournals.org/doi/10.7326/ANNALS-25-00253
III Watchman Air Embolism Alerts
- Looming Pay Cut to LAAO Triggers Objection From Card Groups
https://www.medscape.com/viewarticle/looming-pay-cut-laao-triggers-objection-card-groups-2025a1000l0j
- FDA Alert https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-watchman-access-system-issue-boston-scientific
IV Switching Oral Anticoagulants in Frail Older Adults Patients
- FRAIL AF Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485
- COMBINE AF Substudy https://doi.org/10.1016/j.jacc.2025.05.060
- The Most Important Study From ESC: FRAIL-AF https://www.medscape.com/viewarticle/996063
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.7 | This podcast is intended for health care professionals only. |
| 0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.6 | Hi, everyone. |
| 0:15.8 | This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for August 8th, |
| 0:23.5 | 2025. This week, listener feedback on the surpassed cardiovascular outcomes trial, AF ablation, and the |
| 0:30.9 | limits of meta-analyses, a watchman alert from FDA, and oral anticoagulation choices in elderly patients. |
| 0:40.0 | First up is that diabetes specialist Andreas Anderson from the Herlov Hospital in Copenhagen, |
| 0:46.6 | which I have visited and given a lecture at, writes in about my coverage of the surpass cardiovascular |
| 0:53.0 | outcomes trial comparing terseptide |
| 0:55.4 | versus duloaglutide last week. The study results came as a press release. Eli Lilly, the makers |
| 1:03.0 | their teusepartite, announced that their drug proved non-inferior to dulootide for cardiovascular |
| 1:09.5 | outcomes in patients with diabetes and established heart disease. |
| 1:14.2 | The results of the surpassed CVOT trial was that the risk of cardiovascular death heart attack stroke |
| 1:19.8 | was 8% lower for transepatide versus dula glutide that hazard ratio is 0.92, |
| 1:27.1 | and the conference intervals went from 0.83 to 1.01, |
| 1:31.3 | but this was a non-inferiority trial and it met the non-inferiority limits. |
| 1:37.3 | Treasepotide also showed consistent results across all three components of the Mace 3 composite endpoint. The rate of all-caused mortality, |
| 1:47.5 | interestingly, was 16% lower for terseptitide versus duaglutide, and nanazard ratio was 0.84 |
| 1:54.6 | and statistically significant with conference intervals below 1.0. There were also positive results in secondary endpoints, |
| 2:03.2 | such as a slower slope of EGFR decline, |
| 2:06.9 | more reduction of hemoglobin A1C, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.